195 related articles for article (PubMed ID: 24056704)
21. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
Lehtinen T; Tolonen A; Turpeinen M; Uusitalo J; Vuorinen J; Lammintausta R; Pelkonen O; Scheinin M
Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
[TBL] [Abstract][Full Text] [Related]
22. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
[TBL] [Abstract][Full Text] [Related]
23. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
25. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Ma X; Cheung C; Krausz KW; Shah YM; Wang T; Idle JR; Gonzalez FJ
Drug Metab Dispos; 2008 Dec; 36(12):2506-12. PubMed ID: 18799805
[TBL] [Abstract][Full Text] [Related]
26. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
[TBL] [Abstract][Full Text] [Related]
28. Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs.
Van der Heyden S; Croubels S; Gadeyne C; Ducatelle R; Daminet S; Murua Escobar H; Sterenczak K; Polis I; Schauvliege S; Hesta M; Chiers K
Am J Vet Res; 2012 Jun; 73(6):900-7. PubMed ID: 22620706
[TBL] [Abstract][Full Text] [Related]
29. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide.
Zhang L; Fitzloff JF; Engel LC; Cook CS
Xenobiotica; 2001 Feb; 31(2):73-83. PubMed ID: 11407536
[TBL] [Abstract][Full Text] [Related]
30. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
[TBL] [Abstract][Full Text] [Related]
31. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
32. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
33. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
35. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
36. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
37. Tertiary Oxidation of Deoxycholate Is Predictive of CYP3A Activity in Dogs.
Zeng W; Gui L; Tan X; Zhu P; Hu Y; Wu Q; Li X; Yang L; Jia W; Liu C; Lan K
Drug Metab Dispos; 2021 May; 49(5):369-378. PubMed ID: 33674269
[TBL] [Abstract][Full Text] [Related]
38. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
[TBL] [Abstract][Full Text] [Related]
39. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
[TBL] [Abstract][Full Text] [Related]
40. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Goel S; Cohen M; Cömezoglu SN; Perrin L; André F; Jayabalan D; Iacono L; Comprelli A; Ly VT; Zhang D; Xu C; Humphreys WG; McDaid H; Goldberg G; Horwitz SB; Mani S
Clin Cancer Res; 2008 May; 14(9):2701-9. PubMed ID: 18451235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
